Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs General Dynamics Corporation (GD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs General Dynamics Corporation — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $280 (market cap $39.89B), while General Dynamics Corporation trades at $375.84 (market cap $101.43B). The key difference: General Dynamics Corporation is far larger — about 2.5× Alnylam Pharmaceuticals, Inc.'s market cap, and General Dynamics Corporation pays a 1.7% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | GD | |
|---|---|---|
Market Cap | $39.89B | $101.43B |
Sector | Health | Industrials |
52-Week High | $491.22 | $376.88 |
52-Week Low | $278.09 | $297.05 |
Enterprise Value | $38.15B | $107.61B |
Dividend Yield | — | 1.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
General Dynamics (GD) trades at $375.06, up 0.12% today, near its 52-week high with strong technical momentum. The stock shows robust fundamentals, including consistent earnings beats, revenue growth to $52.55B in 2025, and healthy margins. Analyst sentiment is bullish, with a consensus price target of $395.83, supported by a backlog surge to $130.8B in Q1 2026 (Seeking Alpha, 2026-07-02).
Outlook remains positive due to defense spending tailwinds and submarine contract wins, but risks include execution delays and valuation concerns. The stock offers growth potential with a 5.6% upside to consensus target, though high RSI levels suggest near-term overbought conditions. Investors should weigh strong cash flow and dividend stability against geopolitical and supply chain uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About General Dynamics Corporation
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, combat systems, marine, and technologies. The company's aerospace segment creates Gulfstream business jets. Combat system produces land-based combat vehicles, such as the M1 Abrams tank. The marine subsegment creates nuclear-powered submarines, among other things. The technologies segment contains two main units, an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computers, intelligence, surveillance, and reconnaissance capabilities to the military.
Read more on GD →
